Cite
HARVARD Citation
Shi, J. et al. (2021). Occurrence of hypertension during third‐line anlotinib is associated with progression‐free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial. Thoracic cancer. 12 (17), pp. 2345-2351. [Online].